本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
KUALA LUMPUR, Malaysia, Feb. 26, 2026 /PRNewswire/ -- Every day across Malaysia, café owners plan their menus, small restaurants juggle rising costs, farmers look for better access to markets, and chefs search for fresher, more reliable ingredients. MYFOOD Expo 2026 brings these people together in one place, creating a shared space where ideas, solutions and opportunities meet, all with the aim of building a stronger and more resilient food future for Malaysia and its rakyat, the everyday people who produce, prepare and depend on food. Returning to the Kuala Lumpur Convention Centre (KLCC) from 7-9 May 2026, MYFOOD Expo 2026 will be held concurrently with the International Café & Beverage Show (ICBS), forming one of the region's most comprehensive gatherings for the food, café and beverage community. Previous editions welcomed more than 13,000 attendees from 55 countries, supported by 17 industry conference speakers, reflecting the growing relevance of MYFOOD as a platform that attracts both local and international participation. Organized by Opulence Exhibition Services Sdn Bhd and supported by the Ministry of Agriculture and Food Security, MYFOOD Expo 2026 is built on a simple but important belief that food security and economic sustainability begin with strong local businesses and a connected food ecosystem. The Expo is held in collaboration with industry players, associations, academia, state governments and community stakeholders, recognizing that resilience in food systems requires collective effort across sectors and regions. At its heart, MYFOOD Expo 2026 is about connecting the journey of food from farm to market. For farmers and producers, it offers direct access to chefs, café owners and buyers who value quality and reliability. For cafés and small restaurants, it provides opportunities to discover better sourcing, smarter processes and new partnerships that can improve margins and consistency. For chefs and food entrepreneurs, it is a place to exchange ideas, stay ahead of consumer trends and build relationships that turn creativity into sustainable business. The Expo focuses on what Malaysians actually cook, serve and consume every day, fresh and semi-fresh produce, locally made ingredients and practical food solutions that support healthier choices without losing sight of commercial realities. By strengthening local production and shortening supply chains, MYFOOD Expo supports the principles of the Slow Food movement in a practical way, ensuring that food systems remain stable and accessible even during times of global uncertainty caused by climate events, supply disruptions or geopolitical conflict. When local food businesses are productive and resilient, the economic impact stays within communities. This protects livelihoods, stabilizes supply and ensures that the rakyat are not disproportionately affected by external shocks. In this sense, MYFOOD Expo is not just about food, it is about economic sustainability, social resilience and long-term security. Knowledge sharing is a key part of this journey. University Putra Malaysia (UPM) participates as the Knowledge Partner for MYFOOD Expo 2026, contributing applied expertise in food security, innovation and commercialization. The emphasis is on turning ideas into action, helping local innovations move beyond research and into farms, kitchens, cafés and markets where they can create real impact. With strong participation from government, industry and academia, MYFOOD Expo 2026 offers a timely and meaningful opportunity for food businesses to be part of a growing movement towards collaboration and resilience. For exhibitors, it is a chance to be seen, heard and discovered. For visitors, it is a place to learn, connect and be inspired. For the wider industry, it is a moment to come together and shape what Malaysia eats next. MYFOOD Expo 2026 is more than an exhibition, it is where Malaysia's food community meets to move forward together, for the benefit of businesses, consumers and the rakyat. More information on MYFOOD Expo 2026, including programmes, exhibitors and how to participate, is available at myfood-expo.com. Food businesses, producers, chefs and industry stakeholders are invited to be part of MYFOOD Expo 2026 and join the movement shaping a more resilient food future for Malaysia.
At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to combine more than one omic insight reveals unprecedented biological depth and knowledge, all of which is streamlined by Illumina Connected Multiomics for multimodal data analysis. The combined portfolio delivers new insights for precision diagnostics, targeted therapeutics development, and understanding of tumor microenvironments. "Unlocking the human genome has changed the face of cancer care and opened up demand for the next wave of biological insights," said Jacob Thaysen, chief executive officer at Illumina. "Researchers are rapidly adopting multiomics and informatics technologies that expand our understanding of biology at scale. Illumina's streamlined multiomics workflows are enabling customers to achieve game-changing breakthroughs in oncology, pharmacogenomics, and more." Illumina Spatial Technology decodes complex tissues with ease The human lymphatic system is notoriously difficult to map due to its size and variability among individuals. Spatial technology holds promise to probe biomolecular signatures that can improve the diagnosis and prognosis of cancer and even explain how it metastasizes in the body. Dr. Ioannis Vlachos, PhD, director of the Spatial Technologies Unit within Beth Israel Deaconess Medical Center (BIDMC), leveraged Illumina Spatial Technology and visualization software to investigate human lymph nodes and lymphatic channels. "Our research as an NIH HuBMAP Tissue Mapping Center aims to shed light on the complex function of lymphatic vessels, which are exceptionally challenging samples due to their low adhesion, surrounding adipose tissue, and small size. Illumina Spatial Technology generated high-quality data from samples ranging from very small to quite sizable, producing the first ever whole transcriptome spatial datasets for human lymphatic collector vessels," said Vlachos. "The large capture area and serial sections helped us resolve single‑cell‑thick layers and reconstruct three‑dimensional representations of tissue organization with whole transcriptome capture at 1um resolution. Our institution and the broader research community can use these datasets to answer many possible research questions." In another study conducted by Illumina researchers, Illumina Spatial Technology outperformed other competing technologies for improved sensitivity, higher resolution, and higher throughput at a lower cost. The study mapped breast cancer progression across a range of precancerous to high-grade ductal carcinomas. Whole-transcriptome profiling revealed unexpected nuances of tumor microenvironments, including identification of a novel set of cancer-associated fibroblasts. Researchers found more than 2000 unique transcripts in each cell, showing an unprecedented level of sensitivity. "Each tumor is unique and its gene expression is never uniform," said Cande Rogert, vice president and global head of advanced sciences at Illumina. "By interrogating a large surface area of tissue at high resolution, we were able to analyze the tumor genetics within their real context and identify new cell subtypes. The resulting multiomic insights provide additional information and have the potential to drive more precise therapeutic development." Illumina 5-base solution delivers epigenetic context for cancer diagnostics A team of researchers from Broad Clinical Labs, working with hospital research partners in Boston and Europe, recently explored the application of Illumina's 5-base solution to support clinical research for pediatric kidney cancer. This type of cancer typically requires invasive surgical procedures to diagnose, monitor, and treat that are not always feasible. The researchers are seeking genomic alternative approaches. Existing translational research ctDNA assays can miss disease signals in very rare tumors such as Wilms and rhabdoid. Illumina's 5-base solution enabled simultaneous genomic and methylation profiling to add additional epigenomics signals that identify cases missed by conventional approaches. Illumina 5-base whole genomes from renal cancer patients were tested in methylation-based classifiers and were able to predict the presence of rhabdoid tumors missed by genomics-only methods. Future work will expand 5-base profiling to additional FFPE and cfDNA samples, with the goal of training advanced machine learning models. These efforts may ultimately provide clinicians with more accurate diagnostic insights and improve outcomes for patients. "Combining these molecular signals in a single, scalable process can help us develop non-invasive diagnostics for cancers," said Carrie Cibulskis, director of cancer genomics at Broad Clinical Labs. "We're working toward a minimally invasive methylation-aware assay for cancer diagnosis and treatment selection." Integrated multiomics improves understanding of advanced ovarian cancer Nearly 80% of ovarian cancers are diagnosed at advanced stages, where survival drops to about 30%. When caught early, survival exceeds 90%. For women presenting with an adnexal mass, accurately distinguishing between benign and malignant disease is critical to guiding appropriate referral and surgical care, yet current diagnostic tools lack sufficient accuracy to reliably support these decisions. Bodour Salhia, PhD, a professor of cancer biology at the University of Southern California's Keck School of Medicine applied Illumina's 5-base solution, Illumina Protein Prep, and Illumina Spatial Technology to adnexal masses. The method enabled them to more easily differentiate between cancerous and benign tumor types using cell-free DNA and explore more sensitive ways to gain deeper biological context for ovarian cancer. Results included the first reported spatial analyses of adnexal masses and revealed localized tumor biology not previously reported. "These findings create a multiomic framework for ovarian cancer research and lay the groundwork for an effective liquid biopsy in particularly challenging ovarian cancers with the potential to transform diagnostic practices and outcomes," said Salhia. "Layering the omics gave us a winning combination, providing more context for earlier cancer identification." Illumina's 5-base solution allowed for sensitive, integrated genetic and methylation analysis of tumor samples without compromising specificity. The methylation signals separated malignant and benign samples better than traditional approaches, which can often fail to separate cell types. Illumina Protein Prep allowed the researchers to identify novel gene sets, proteins, and pathways in ovarian cancer, creating new lines of inquiry in cancer biology research, biomarker and drug development. Layering Protein Prep and 5-base data through a custom pipeline in Illumina Connected Multiomics quickly resolved a false positive case. The layered approach helped researchers establish parameters for targeted exploration of gene expression in spatial data. Using Illumina Spatial Technology, transcriptomic data helped to resolve signals driving false positive results. Illumina Connected Multiomics accelerates sample-to-answer pipeline Multimodal analytics from Illumina Connected Multiomics provides deeper insights and overcomes the fragmented, siloed views produced by isolated assays, empowering researchers with a new understanding of cancer mechanisms, tumor heterogeneity, and potential therapeutic targets. "Multiomics is advancing our understanding of disease from a single dimension to a more complete biological landscape," said Jenny Zheng, Senior Vice President and General Manager of Greater China at Illumina. "Illumina is committed to deeply integrating multiomics innovation with bioinformatics and AI capabilities to build an integrated multiomics ecosystem that accelerates the journey from sample to insight. We will continue to collaborate with local partners, as well as clinical and research experts, to accelerate the localization and adoption of innovative multiomics solutions. By driving synergistic development between research and transformation, we aim to ensure that technological innovation delivers meaningful value to patients, healthcare systems, and drug discovery and development, faster." Illumina unveiled new product updates and customer data during the Gold Sponsor Workshop at the Advances in Genome Biology and Technology (AGBT) annual meeting in Orlando. Learn more about Illumina's activity at AGBT here. Use of forward-looking statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in researching, developing and launching new technologies, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables and develop reliable software solutions; (iii) our ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services, and (iv) the acceptance and adoption by customers of our newly launched or updated products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad Clinical Labs is among first to adopt product, which was previously known as "constellation mapped read technology" SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease. With an incredibly simple workflow, TruPath Genome eliminates traditional library prep. In about 10 minutes of hands-on time, TruPath Genome generates 16 whole genomes per day, nearly double the throughput of competing long-read methods, and with fewer errors. TruPath Genome leverages novel on-flow cell library preparation with patterned flow cell technology and advanced informatics to seamlessly add long-distance insights for comprehensive variant detection. DRAGEN™ algorithms tuned to incorporate proximity information from TruPath flow cells improve read alignment and variant calling, extending Illumina high-quality reads to difficult-to-map regions, variant phasing, structural variants, short tandem repeats (STR), and clinically relevant paralogous genes. TruPath Genome fully phases up to 98% of genes. "With TruPath Genome, we are pushing the boundaries of genomics and setting a new standard for genetic and rare disease research," said Steve Barnard, PhD, chief technology officer of Illumina. "In rare disease, you're often looking for a variant needle in a genomic haystack—and comprehensiveness, accuracy, and confidence matter. This technology unlocks rapid answers to shed light on the genomic drivers of genetic disease with an ease that was never thought possible." TruPath Genome delivers a highly cost-effective whole genome workflow, at an industry standard depth of at least 30x coverage with single-use flow cell, which is critical in clinical research. Data presented at AGBT illustrates a short-read path to long-distance insightData presented today at AGBT and in previous publications illustrates how TruPath Genome is already shedding light on some of the most challenging genetic diseases, including spinal muscular atrophy, kidney disease, and complex adrenal disorders. Researchers at University Medical Center Utrecht presented data evaluating TruPath Genome in challenging rare disease samples, with a particular focus on long–range phasing performance required to support non–invasive prenatal diagnostic (NIPD) assays, as well as resolution of difficult genomic regions and complex structural variants. "TruPath Genome enabled us to consolidate multiple analyses into a single, easy–to–implement whole–genome assay," said Marcel Nelen, PhD, head of the Genome Diagnostic Laboratory at UMC Utrecht. "Despite the simplicity of the workflow, we achieved megabase–scale phasing, full resolution of clinically relevant genes, and improved interpretation of difficult regions—even a particularly challenging case in the notoriously complex SMN1/SMN2 region—as well as complex structural variants. This represents an important step toward a single assay capable of addressing many rare disease research questions without additional orthogonal testing." At the recent Festival of Genomics & Biodata in London, researchers from the University of Exeter shared data on their pilot of TruPath Genome, which found that the technology resolved highly complex genomic regions, including a gene known to be associated with inherited adrenal disorders. While current short-read WGS requires parental samples to identify compound heterozygotes, TruPath Genome offers a single-sample path to these insights, improving coverage for samples processed without parental data. "TruPath Genome opens up a future where every patient affected by a rare genetic condition can receive rapid comprehensive whole-genome testing to end diagnostic odysseys and identify possible precision treatments," said Emma Baple, PhD, professor of Genomic Medicine at the University of Exeter and medical lead for the NHS England Rapid Genome Sequencing Service for Critically Unwell Children. "In Exeter, we have been privileged to evaluate the TruPath technology and seen the potential to change the lives of affected children and their families. We are eager to see how this innovation evolves, as these types of solutions will transform how rare conditions are diagnosed." Broad Clinical Labs is among the first to adopt TruPath Genome, which will make this important technology available to their collaborators in rare disease research. "TruPath means a more comprehensive genome to drive our research," said Sean Hofherr, PhD., FACMG, chief of clinical strategy and product development, Broad Clinical Labs. "This technology delivers an impressive ability to interrogate even the most challenging variants in the genome, all in a stunningly simple workflow. And, being able to run it on the NovaSeq X Plus is attractive." More than 30 early access customers have been piloting the technology over the past 16 months, including GeneDx, Rady Children's Hospital, and Baylor College of Medicine. Baylor College of Medicine recently published a pre-print on the technology in medRxiv. "We remain committed to advancing the accessibility of genomics through continuous innovation, delivering streamlined end-to-end workflows and comprehensive genomic insights to address the most challenging rare genetic diseases," said Jenny Zheng, Senior Vice President and General Manager of Greater China at Illumina. "In Greater China, we will deepen our collaboration with clinical and research experts to accelerate the transformation of cutting-edge technologies from research into clinical practice, ensuring our innovations truly reach patients. On this occasion of Rare Disease Day, we stand ready to illuminate the path forward for more families navigating the diagnostic odyssey." The TruPath Genome launch was unveiled today during the Gold Sponsor Workshop at the Advances in Genome Biology and Technology (AGBT) annual meeting in Orlando. Register here for the replay. TruPath Genome was previously referred to as "constellation mapped read technology." Learn more about TruPath Genome here. * TruPath Genome carries a list price of $395 USD (exclusive of duties and shipping), including all consumables and analysis. Use of forward-looking statementsThis release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables and develop reliable software solutions; and (iii) the acceptance and adoption by customers of our newly launched or updated products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter. About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
TAIPEI, Feb. 25, 2026 /PRNewswire/ -- A news article from Mnews: Imagine standing beneath a 21-meter tower of glowing light while drones paint the night sky above you, fireworks burst overhead, and the sounds of Irish tap dancers echo through the warm evening air. This is the 2026 Taiwan Lantern Festival — and it's happening in Chiayi County from March 3 to 15, 2026. Mazu of Peitian Temple If you've been looking for a reason to visit Taiwan in early spring, this is it. Taiwan Lantern Festival is one of Asia's most beloved annual celebrations, the Taiwan Lantern Festival marks the end of the Lunar New Year period with an explosion of light, color, and culture. Each year it rotates to a different city, and 2026 brings it to Chiayi County — a region nestled between the mountains of Alishan and the coastline of the Taiwan Strait, and one of the island's most underrated destinations. This year's theme, "Glow with Taiwan, Light Up Chiayi," promises far more than pretty lanterns. Spread across 16 themed zones, the festival weaves together Chiayi's identity as a place of modern agriculture, environmental innovation, youth creativity, and deep cultural roots. The festival has curated 12 official "must-see" attractions, and several of them are genuinely extraordinary. The centerpiece is "Glow of Alishan," a towering 21-meter main lantern synchronized to a full sound and light show — the kind of spectacle you'll be describing to friends back home for years. Each evening, massive drone light shows choreograph hundreds of illuminated aircraft into shifting patterns above the festival grounds, followed by celebratory fireworks displays. For performing arts lovers, the international lineup is remarkable. Expect performances from France's Cavalcade of White Horses, high-energy Irish Tap Dancing, the beloved Taiwanese Paper Windmill Theatre, and the iconic Ming Hwa Yuan Arts & Cultural Group. Street carnivals and large-scale parades run throughout the event, meaning there's always something happening whether you wander in on opening night or the last day. Technology fans will want to spend time in the Osaka Expo TECH WORLD Pavilion and the whimsical Super Mario Starry Carnival zone — a nod to Taiwan's embrace of global pop culture and digital innovation. Chiayi is very accessible by high-speed rail. The Chiayi HSR Station connects you to Taipei in under 90 minutes, and free shuttle buses run directly from both the HSR station and the TRA Chiayi Station into the festival grounds. If you're driving, seven free parking lots offer over 10,000 spaces — though shuttles are genuinely the easier option given expected crowd sizes in the millions. The official festival website is available in English, Japanese, and Korean at 2026taiwanlanternfestival.org/En , where you'll find zone maps, event schedules, and everything you need to plan your visit. A dedicated transportation site provides live updates on parking, shuttle routes, and traffic — handy to bookmark on your phone before you arrive. Chiayi itself is worth building a longer trip around. The gateway to Alishan National Scenic Area, Taiwan's famous high-mountain forest railway, and home to exceptional local cuisine — turkey rice being the dish you absolutely must try — the county rewards visitors who linger beyond the festival grounds. Whether you're a first-time visitor to Taiwan or a returning traveler finally venturing beyond Taipei, the 2026 Taiwan Lantern Festival offers a genuinely unmissable window into the warmth, creativity, and spectacle that makes this island so special. Don't miss it. Original link: https://www.mnews.tw/story/20260225sot1300009 Sailing the World
International Maritime Organization's Cape Town Agreement will help save lives and fight illegal fishing—protecting the ocean and the people who depend on it LONDON, Feb. 25, 2026 /PRNewswire/ -- The Pew Charitable Trusts today welcomed the news that the Cape Town Agreement (CTA) has received sufficient support from major fishing nations across the globe—including Argentina, which acceded to the treaty today—to begin to be enforced starting next year. This binding international treaty will improve fishing vessel standards to ensure crew and observer safety and is an important step forward for the fight against illegal, unreported, and unregulated (IUU) fishing. The CTA will protect fishers' lives by establishing standards for industrial vessel construction and related seaworthiness, decking, heating, emergency procedures and other safety and life-saving measures. Before this landmark treaty, few global standards or international legal obligations protected fishers at sea. Research from the FISH Safety Foundation, commissioned by Pew, estimates that more than 100,000 people in the fishing sector are killed each year. The CTA's focus on safety could help prevent many deaths. Importantly, increasing safety standards on fishing vessels will also help efforts to fight IUU fishing. In an effort to maximize profits, operators who fish illegally often cut corners with how they manage their vessels, further endangering workers in one of the world's most hazardous professions. More governance, and standardized control over vessel safety provisions, will increase opportunities to detect and prevent IUU fishing. Adopted by the International Maritime Organization in 2012, the CTA, which applies primarily to new vessels 24 meters or longer, will enter into force next year now that 28 States (several more than the 22 required) have ratified it. To enter into force, the agreement also had to cover at least 3,600 vessels, and that benchmark has also been exceeded with the latest round of ratifications. The CTA joins two longstanding international agreements that make it more difficult for unscrupulous operators to exploit gaps in fishing regulations. These include the Agreement on Port State Measures (PSMA) by the Food and Agriculture Organization of the United Nations, which requires parties to strengthen and harmonize port controls, and the International Labor Organization's Work in Fishing Convention, which establishes binding safety and labor standards at sea. Momentum for stronger ocean governance has accelerated. Since 2022, four major international agreements have been adopted or entered into force, including the Convention on Biological Diversity Kunming-Montreal Global Biodiversity Framework in 2022, the World Trade Organization Agreement on Fisheries Subsidies in 2025, the high seas treaty, or United Nations Agreement on the Conservation and Sustainable Use of Marine Biological Diversity of Areas beyond National Jurisdiction, in January 2026, and now the CTA. Together, they mark a decisive shift towards efforts to secure the long-term health of marine ecosystems and people alike. Peter Horn, who directs efforts to end illegal fishing at The Pew Charitable Trusts, issued the following statement: "With activation of the Cape Town Agreement, governments have taken a momentous step towards improving fishers' safety at sea; strengthening efforts to end illegal, unreported and unregulated fishing; and increasing the sustainability of fisheries through better oversight and governance of fishing fleets. "Until now, fishers lacked the same safety protections as other seafarers. And with more than 100,000 people killed each year in the global fishing sector, protective action was critical. When this treaty enters into force next year, it will dramatically improve the standards of life in the fishing industry—and, in turn, reduce fishing-related deaths. "The Cape Town Agreement comes on the heels of other important ocean treaties. But these ambitious plans for sustainable governance are only as good as their implementation. States must now do their part to turn words into action and deliver protections not only for global fisheries and fishers themselves, but for the entire ocean ecosystem." Founded in 1948, The Pew Charitable Trusts uses data to make a difference. Pew addresses the challenges of a changing world by illuminating issues, creating common ground, and advancing ambitious projects that lead to tangible progress. Media Contact: Leah Weiser, 202-591-6761, lweiser@pewtrusts.org
ORLANDO, Fla., Feb. 24, 2026 /PRNewswire/ -- accesso Technology Group (AIM: ACSO), the leading technology partner to the leisure and entertainment industry, today announced the renewal of its long-standing partnership with the State Fair of Texas through 2030. The Fair will continue to rely on accesso ShoWareSM to power its ticketing operations, reinforcing a shared commitment to operational excellence, guest experience and ongoing innovation. accesso_logo_v2 Originally established in 1886, the State Fair of Texas promotes Texas agriculture, education, and community involvement through quality entertainment in a family-friendly environment. The Fair runs 24 consecutive days each fall, making it the longest-running fair in the country and one of the largest. It regularly draws over 2 million visitors. Over the course of their partnership, the State Fair of Texas and accesso have worked closely to evolve the ticketing experience in step with changing guest expectations. For an event that handles an extremely high volume of transactions daily, reliability, speed and flexibility are essential. The Fair credits accesso's consistency, responsiveness and ability to operate at scale as key factors in the continued success of the relationship. "The number one reason we're renewing? The support and flexibility," said Jennifer Schuder, Senior Vice President, Customer Engagement at the State Fair of Texas. "With Accesso, we have a true partner. They understand our scale, our sophisticated approach to pricing, and they stand alongside us every step of the way." This past season, the Fair introduced accessoPay with Cybersource payment processing through accesso ShoWare, expanding support for digital wallets and enabling tap-to-pay transactions. More than 30 percent of all payments were completed using digital wallets, giving guests the fast, convenient options they wanted and helping drive more purchases online, while also reducing wait times when entering the fairgrounds. In addition, the Fair implemented a proof-of-concept integration between accesso ShoWare and its parking vendor, allowing for pre-sold parking. This capability gave guests more control when planning their visit and helped improve entry flow. Following a successful rollout, the Fair plans to expand this offering in future seasons. "Supporting an event of this scale requires more than technology. It requires trust, collaboration and a deep understanding of operational realities. The State Fair of Texas is thoughtful, innovative and relentlessly focused on delivering a great guest experience. We're proud of what we've built together and excited to continue evolving the partnership in the years ahead," said Joe Wettstead, Vice President of Client Success at accesso. accesso ShoWare is trusted by venues and events worldwide to manage complex ticketing, pricing, and access requirements at scale, helping operators deliver reliable, high-performance experiences even under peak demand. About accesso Technology Group plc accesso is the leading global provider of patented and award-winning technology solutions that redefine the guest experience. accesso provides connected ticketing and eCommerce, virtual queuing, restaurant and retail point of sale, distribution, mobile apps and experience management for more than 1,100 venues worldwide. Our technology helps operators streamline operations, increase revenue and improve the guest journey. We deliver a high volume of product enhancements year-round and continuously invest in R&D to help venues and operators adapt to evolving guest needs. accesso is a public company, listed on AIM: a market operated by the London Stock Exchange. Learn more at accesso.com or follow accesso on X (Twitter), LinkedIn and Facebook.
A12 藝術空間
Agriculture
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
